HK1252062A1 - Nut中线癌的治疗 - Google Patents

Nut中线癌的治疗 Download PDF

Info

Publication number
HK1252062A1
HK1252062A1 HK18111394.9A HK18111394A HK1252062A1 HK 1252062 A1 HK1252062 A1 HK 1252062A1 HK 18111394 A HK18111394 A HK 18111394A HK 1252062 A1 HK1252062 A1 HK 1252062A1
Authority
HK
Hong Kong
Prior art keywords
alkyl
group
alkylene
cycloalkyl
heterocycloalkyl
Prior art date
Application number
HK18111394.9A
Other languages
English (en)
Chinese (zh)
Inventor
S‧B‧兰多
S‧B‧蘭多
M‧H‧卡格依
Original Assignee
腾沙治疗公司
騰沙治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 腾沙治疗公司, 騰沙治療公司 filed Critical 腾沙治疗公司
Publication of HK1252062A1 publication Critical patent/HK1252062A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK18111394.9A 2015-06-26 2016-06-24 Nut中线癌的治疗 HK1252062A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562185203P 2015-06-26 2015-06-26
US62/185,203 2015-06-26

Publications (1)

Publication Number Publication Date
HK1252062A1 true HK1252062A1 (zh) 2019-05-10

Family

ID=56409188

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111394.9A HK1252062A1 (zh) 2015-06-26 2016-06-24 Nut中线癌的治疗

Country Status (14)

Country Link
US (1) US20180193350A1 (https=)
EP (1) EP3314005A1 (https=)
JP (1) JP2018520124A (https=)
KR (1) KR20180035785A (https=)
CN (1) CN107787227A (https=)
AR (1) AR105124A1 (https=)
AU (1) AU2016283020A1 (https=)
BR (1) BR112017028178A2 (https=)
CA (1) CA2989313A1 (https=)
HK (1) HK1252062A1 (https=)
IL (1) IL256186A (https=)
MA (1) MA42249A (https=)
MX (1) MX2017016337A (https=)
WO (1) WO2016210275A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
CA2929652A1 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
SG11201607108XA (en) 2014-02-28 2016-09-29 Tensha Therapeutics Inc Treatment of conditions associated with hyperinsulinaemia
BR112017008714A2 (pt) 2014-10-27 2017-12-19 Tensha Therapeutics Inc inibidores de bromodomínio
EP4629984A1 (en) * 2022-12-06 2025-10-15 BioVentures, LLC Development of potent dual hdac/brd4 inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO2009084693A1 (ja) 2007-12-28 2009-07-09 Mitsubishi Tanabe Pharma Corporation 抗癌剤
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
ES2563057T3 (es) 2009-11-05 2016-03-10 Glaxosmithkline Llc Inhibidor de bromodominio de benzodiazepina
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
RS54645B1 (sr) 2009-11-05 2016-08-31 Glaxosmithkline Llc Benzodiazepin kao inhibitor bromodomena
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
PL2902030T3 (pl) * 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
US9085582B2 (en) 2010-06-22 2015-07-21 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012151512A2 (en) 2011-05-04 2012-11-08 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721031B1 (en) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
SG11201607108XA (en) 2014-02-28 2016-09-29 Tensha Therapeutics Inc Treatment of conditions associated with hyperinsulinaemia

Also Published As

Publication number Publication date
EP3314005A1 (en) 2018-05-02
IL256186A (en) 2018-02-28
US20180193350A1 (en) 2018-07-12
AU2016283020A1 (en) 2018-01-04
JP2018520124A (ja) 2018-07-26
BR112017028178A2 (en) 2018-08-28
MX2017016337A (es) 2018-11-22
AR105124A1 (es) 2017-09-06
KR20180035785A (ko) 2018-04-06
CN107787227A (zh) 2018-03-09
WO2016210275A1 (en) 2016-12-29
MA42249A (fr) 2018-05-02
CA2989313A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
HK1252062A1 (zh) Nut中线癌的治疗
RU2566821C2 (ru) Модулятор nmda-рецептора со стабилизированной вторичной структурой и его применение
Haftchenary et al. Potent targeting of the STAT3 protein in brain cancer stem cells: a promising route for treating glioblastoma
AU2023200537B2 (en) Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
KR20230005175A (ko) Eif4a 억제제 조합물
AU2017339781B2 (en) Formulations for administration of eflornithine
WO2019246570A1 (en) Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
EA038337B1 (ru) Ингибиторы ezh2 для лечения лимфомы
US11896589B2 (en) Diazinyl amino acridines and medical uses thereof
CN101801401A (zh) 激酶蛋白质结合抑制剂
AU2014361814A1 (en) Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders
IL297486A (en) Gper proteolytic targeting chimeras
US10420748B2 (en) Methods of treatment associated with the granulocyte colony-stimulating factor receptor
US20250170097A1 (en) Cathepsin inhibitors and use thereof in a method for detecting and treating resistance to immunotherapy
JP2019507116A (ja) エストロゲン受容体を活性化する新規化合物ならびにその組成物および使用方法
JP2024031105A (ja) 線維症治療又は予防薬
CN115477634A (zh) 用于镇痛的化合物及其医药用途
WO2009034464A2 (en) Indole related compounds with physiological activity
US20220227717A1 (en) Allosteric activators of the alpha1a-adrenergic receptor
US20250122193A1 (en) Novel pyridocarbazolium compounds and medical uses thereof
CN100377709C (zh) 受体酪氨酸激酶抑制剂的制药用途及相关检测方法
JP2021532188A (ja) μオピオイド受容体のアロステリックモジュレーター
HK1239671B (zh) 丙烯酸类衍生物、其制备方法及其在医药上的用途
HK1147417A (en) Kinase protein binding inhibitors